Skip to main
CASI
CASI logo

CASI Pharmaceuticals (CASI) Stock Forecast & Price Target

CASI Pharmaceuticals (CASI) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CASI Pharmaceuticals Inc. is anticipated to experience robust revenue growth, with projections of reaching $36 million in 2023 and increasing to $59 million in 2024, bolstered by the launch of new products and strengthening market position. The recent approval of CNCT19 for treating relapsed and refractory B-cell acute lymphoblastic leukemia positions the company favorably, as it is expected to capture significant market share due to its cost advantage and first-mover status in China. Additionally, promising results from the Phase 1 study of BI-1206 indicate strong potential for its immune-modulating therapies, further enhancing the company's growth outlook.

Bears say

CASI Pharmaceuticals Inc. is facing a negative financial outlook, primarily driven by a significant 59% year-over-year decline in revenues attributed to increased generic competition for its lead product, Evomela, in the Chinese market. The anticipated launch of CNCT19 has been delayed from the first quarter to the fourth quarter of 2024, further complicating the company's growth prospects, particularly given the lowered probability of success for this key product. Additionally, projections indicate a net loss of $1.93 per share for 2023, reflecting fundamental challenges in revenue generation and increased competition.

CASI Pharmaceuticals (CASI) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CASI Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CASI Pharmaceuticals (CASI) Forecast

Analysts have given CASI Pharmaceuticals (CASI) a Strong Buy based on their latest research and market trends.

According to 4 analysts, CASI Pharmaceuticals (CASI) has a Strong Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CASI Pharmaceuticals (CASI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.